Considerations for drug trials in hypertrophic cardiomyopathy

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Hypertrophic cardiomyopathy (HCM) is a complex genetic heart disease with serious risks.
• Current management focuses on symptom relief and sudden cardiac death prevention.
• There is a long-standing need for disease-modifying therapies in HCM.

Purpose of the Study:

• To review key considerations for designing and interpreting clinical trials in HCM.
• To discuss the role of novel therapies, including mavacamten, in HCM management.
• To highlight challenges in patient selection, outcome measurement, and trial design for HCM.

Main Methods:

• Review of recent and ongoing randomized clinical trials in HCM.
• Discussion of patient stratification based on genotype, phenotype, and symptoms.
• Analysis of evidence for clinical and mechanistic outcome measures.
• Consideration of trial duration and sample size requirements.

Main Results:

• Mavacamten, a novel oral myosin inhibitor, has been recently approved.
• HCM clinical trials require careful consideration of patient heterogeneity.
• Standardized outcome measures and appropriate trial designs are crucial for evaluating new therapies.

Conclusions:

• The landscape of HCM treatment is shifting towards disease modification.
• Optimizing clinical trial design is essential for advancing HCM therapeutics.
• Understanding trial challenges will facilitate the development of effective HCM treatments.